CURRICULUM VITAE
`S. David Kimball, Ph.D.
`13 Charred Oak Lane
`East Windsor, New Jersey 08520
`
`
`
`
`(848) 932-4550 (Knightsbridge office) kimball@rutgers.edu
`
`(732) 668-9647 (cell) sdavidkimball@gmail.com
`
`
`
`
`RESEARCH EXPERIENCE
`
`
`
`
`
`
`
` Rutgers University, Piscataway, NJ
`
`Associate Vice President, Research Commercialization (2014-)
`
`Associate Vice President, Translational Sciences (2013-)
`
`Research Professor I (2011-)
`
`Senior Scientific Advisor to the Vice President for Research (2012-2013)
`
`Scientific Founder, Z53 Therapeutics (2016-)
`
`
`
`
`
`
`
`
`
`
`
` Hydra Biosciences, Cambridge, MA
` Consulting Chief Scientific Officer (2011-2012)
`
` Chief Scientific Officer (2008-2011)
`
`Ongoing tactical and strategic leadership of all drug discovery and development activities
`addressing Hydra’s TRP ion channel targets for pain and inflammation. Responsibility
`for guiding and mentoring external research alliances.
`
`
`
`Pharmacopeia, Inc., Princeton, NJ
`
`Senior Vice President, Discovery and Nonclinical Development (2007-2008)
`
`
`Responsibility for all drug discovery resources at Pharmacopeia (127 FTE), biology and
`chemistry, screening, external research alliances (35 FTE) and preclinical development.
`
`
`
` Lexicon Pharmaceuticals, Princeton, NJ
`
`Vice President, Medicinal Chemistry (2001-2007)
`
`Responsible for chemistry resources within Lexicon Pharmaceuticals; Medicinal
`Chemistry Department includes process chemistry, analytical chemistry, combinatorial
`chemistry and lead optimization groups. Built and led department at Princeton site of 70
`scientists, recruiting from top universities and pharma; managed chemistry outsourcing,
`delivered multiple compounds into clinical trials.
`Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ
`Research Fellow, Medicinal Chemistry (1982-2001)
`
`Departments of Oncology & Cardiovascular Chemistry
`
`Oncology: Cyclin Dependent Kinase working group co-chair; developed novel kinase
`inhibitor BMS-387032 (SNS-032) for solid tumors; Oncology Licensing Team. Blood
`Coagulation: Thrombin active site inhibitor working group co-chair; discovered
`reversible thrombin active site inhibitors for the treatment of venous and arterial
`thrombosis. Cardiovascular Chemistry: Led research group in the design and
`discovery of novel calcium antagonists for hypertension, anti-anginal and cardiotonic
`agents. Antibiotics: orally active monocyclic beta lactams.
`
`
`
`CONFIDENTIAL
`
`1 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`EDUCATIONAL
`AND TEACHING
`EXPERIENCE
`
`
`
`
`
`
`
`Department of Medicinal Chemistry
`Rutgers University
` Associate Member of Graduate Faculty (1989-2010)
`Courses taught:
`Advanced Medicinal Chemistry I
`Advanced Medicinal Chemistry II
`
`
`
`
`
`
`
`Ph.D. in Organic Chemistry/Chemical Biology
`
`“Total Synthesis of Anthracyclinones”
`
`SUNY at Stony Brook
`
`1982
`
`B.A. (with highest honors)
`
`SUNY at Stony Brook
`
`1978
`
`SUNY Department of Chemistry Teaching Award 1980-81
`SUNY President's Award - Excellence in Teaching 1982
`BMS Excellence Award - Research Leadership 1996
`BMS President’s Award - Drug Formulation Team 1997
`BMS President’s Award - University Recruiting 1998
`
`
`
`
`
`
`
`
`Teaching and
` Research awards
`
`
`
`
`
`
`
`
`
`INVITED LECTURES
`Caltech, Stanford University, University of California Berkeley, University of California
`Davis, University of California Los Angeles, Massachusetts Institute of Technology,
`Duke University, University of Innsbruck.
`Organized and taught Introduction to Medicinal Chemistry at Bristol-Myers Squibb.
`Drug Discovery & Development, Global Clinical Scholars Research Training Program -
`Harvard Medical School (2014 – present)
`
`
`
`SELECT PROFESSIONAL ACTIVITIES
`Board of Directors, Taxis Pharmaceuticals (2015–present)
`Scientific Advisory Board, Genesis Biotechnology Group (2014–present)
`ACS Pharma Leaders Meeting (2005-present)
`Senior Scientific Advisor for Drug Discovery, Madera Biosciences (2011-present)
`Brain Health Institute, Rutgers University (2011-present)
`Long Range Planning Committee, ACS Division of Medicinal Chemistry (2012-2015)
`Scientific Review Board, Alzheimer’s Drug Discovery Foundation (2011-2013)
`Faculty of 1000 (2010-2013)
`Chair, Gordon Research Conference on Medicinal Chemistry, 2005
`Chair, Princeton ACS Symposium, 2007
`Organizer, Drug Discovery in the 21st Century Symposium, 2010
`
`
`
`CONFIDENTIAL
`
`2 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`SELECT PUBLICATIONS
`1. A.R. Blanden, X. Yu, A.J. Wolfe, J.A. Gilleran, D.J. Augeri, R.S. O’Dell, E.C.
`Olson, S.D. Kimball, T.J. Emge, L. Movileanu, D.R. Carpizo, S.N. Loh.
`Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by
`Transporting Zinc into Cells as an Ionophore. Molecular Pharmacology 2015,
`(87) 825-831.
`2. X. Yu, A.R. Blanden, S. Narayanan, L. Jayakumar, D. Lubin, D. Augeri, S.D.
`Kimball, S.N. Loh, D.R. Carpizo. Small Molecule Restoration of Wildtype
`Structure and Function of Mutant p53 Using a Novel Zinc-metallochaperone
`Based Mechanism. Oncotarget 2015, (5) 8879-8892.
`3. Y. Bi, C.D. Dzierba, G. Kumi, C. Fink, Y. Garcia, M. Green, J. Han, S. Kwon, Y.
`Qiao, Y. Zhang, Y. Liu, G. Zipp, Z. Liang, R. Westphal, D. Kimball, J.J. Bronson,
`J.E. Macor. The Discovery of Potent Agonists for GPR88, an Orphan GPCR, for
`the Potential Treatment of CNS Disorders. Bioorg. Med. Chem. Lett. 2015, (25)
`1443-1447.
`4. C.D. Dzierba, Y. Bi, B. Dasgupta, R. Hartz, V. Ahuja, G. Cianchetta, G. Kumi, L.
`Dong, A. Aleem, C. Fink, Y. Garcia, M. Green, J. Han, S. Kwon, Y. Qiao, J.
`Wang, Y. Zhang, Y. Liu, G. Zipp, Z. Liang, N. Burford, M. Ferrante, R. Bertekap,
`M. Lewis, A. Cacace, J. Grace, A. Wilson, R. Westphal, D. Kimball, K. Carson,
`J.J. Bronson, J.E. Macor. Design, Synthesis and Evaluation of Phenylglycinols
`and Phenyl Amines as Agonists of GPR88. Bioorg. Med. Chem. Lett. 2015, (25)
`1448-1452.
`5. G. Zipp, J. Barbosa, M.A. Green, K. Terranova, C. Fink, S. Yu, A. Nouraldeen,
`A. Wilson, K. Savalieva, T. Lanthorn, S.D. Kimball. Novel Inhibitors of the
`High-Affinity L-Proline Transporter as Potential Therapeutic Agents for the
`Treatment of Cognitive Disorders. Bioorg. Med. Chem. Lett. 2014, submitted.
`6. H. Jin, A. Heim-Riether, Q. Han, Z.C. Shi, D. Hackley, S. Reed, J.P. Healy, H.
`Theis, S. Yu, R. Brommage, D. Powell, S.D. Kimball, D.P. Rotella. N-[4-
`(pyrazolo[3,4-d]pyrimidiny-1-yl)-aryl] acetamides as phosphodiesterase 7A
`inhibitors. Bioorg. Med. Chem. Lett. 2014, submitted.
`
`7. J.T. Bagdanoff, M.S. Donoviel, A. Nouraldeen, M. Carlsen, T.C. Jessop, J.
`Tarver, S. Aleem, L. Dong, H. Zhang, L. Boteju, J. Hazelwood, J. Yan, M.
`Bednarz, S. Layek, I.B. Owusu, S. Gopinathan, L. Moran, Z. Lai, J. Kramer, S.D.
`Kimball, P. Yalamanchili, W.E. Heydorn, K.S. Frazier, B. Brooks, P. Brown, A.
`Wilson, W.K. Sonnenburg, A. Main, K.G. Carson, T. Oravecz, D. J. Augeri.
`Inhibition of Sphingosine 1-Phosphate Lyase for the Treatment of Rheumatoid
`Arthritis: Discovery of (E)-1-(4-(1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-
`imidazol-2-yl)ethanone Oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazoly-3-yl)-
`1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J. Med. Chem. 2010 (53)
`8650-8662.
`
`8. H. Jin, Z.-C. Shi, S.D. Kimball et al. (S)-2-Amino-3-(4-(2-amino-6-[R-2,2,2-
`trifluoro-1-(3’-methoxy-biphenyl-4-yl)-ethoxyl]-pyrimidin-4-yl)-
`phenyl)propionic Acid (LX1031): An Orally Active, First-in-Class Tryptophan
`
`CONFIDENTIAL
`
`3 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Hydroxylase Inhibitor for the Treatment of Irritable Bowel Syndrome. J. Med.
`Chem., submitted.
`
`9. R. Bakthavatchalam and S. D. Kimball. Modulators of TRP Ion Channels.
`Annual Reports in Medicinal Chemistry 2010 (45) 37-50.
`
`10. T.C. Jessop, J.E. Tarver, M. Carlsen, A. Xu, J.P. Healy, A. Heim-Riether, Q. Fu,
`J.A. Taylor, D.J. Augeri, M. Shen, T.R. Stouch, R.V. Swanson, L.W. Tari, M.
`Hunter, I. Hoffman, P.E. Keyes, X-C. Yu, M. Miranda, Q. Liu, J.C. Swaffield,
`S.D. Kimball, A. Nouraldeen, A.G.E. Wilson, A. M. DiGeroge Foushee, K.
`Jhaver, R. Finch, S. Anderson, T. Oravecz, K.G. Carson. Lead Optimization and
`Structure-based Design of Potent and Bioavailable Deoxycytidine Kinase
`Inhibitors. Bioorg. Med. Chem. Lett. 2009 (19) 6784-6787.
`
`11. J.E. Tarver, T.C. Jessop, M. Carlsen, D.J. Augeri, Q. Fu, J.P. Healy, A. Heim-
`Riether, A. Xu, J.A. Taylor, M. Shen, P.E. Keyes, S.D. Kimball, X-C. Yu, M.
`Miranda, Q. Liu, J.C. Swaffield, A. Nouraldeen, A.G.E. Wilson, R. Finch, K.
`Jhaver, A. M. DiGeroge Foushee, S. Anderson, T. Oravecz, K.G. Carson. 5-
`Fluorocytosine Derivatives as Inhibitors of Deoxycytidine Kinase. Bioorg. Med.
`Chem. Lett. 2009 (19) 6780-6783.
`
`12. J.T. Bagdanoff, M.S. Donoviel, A. Nouraldeen, J. Tarver, Q. Fu, M. Carlsen, T.
`Jessop, H. Zhang, J. Hazelwood, H. Nguyen, S.D.P. Baugh, M. Gardyan, K.M.
`Terranova, J. Barbosa, J. Yan, M. Bednarz, S. Layek, J. Taylor, A.M. Digeroge-
`Foushee, S. Gopanithan, D. Bruce, T. Smith, L. Moran, E. O’Neill, J. Kramer, Z.
`Lai, S.D. Kimball, Q. Liu, W. Sun, S. Yu, J. Swaffield, A. Wilson, A. Main, K.G.
`Carson, T. Oravecz, D.J. Augeri. Inhibition of Sphingosine-1-Phosphate Lyase for
`the Treatment of Autoimmune Disorders. J. Med. Chem. 2009 (52) 3941-3953.
`
`13. N.C. Goodwin, R. Mabon, B.A. Harrison, M.K. Shadoan, Z.Y. Almstead, Y. Xie,
`J. Healy, L.M. Buhring, C.M. DaCosta, J. Bardenhagen, F. Mseeh, Q. Liu, A.
`Nouraldeen, A.G.E. Wilson, S.D. Kimball, D.R. Powell, D.B. Rawlins. Novel L-
`Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2
`(SGLT2) Inhibitors for the Treatment of Type 2 Diabetes. J. Med. Chem. 2009
`(52) 6201-6204.
`
`14. B.A. Harrison, N.A. Whitlock, M.V. Voronkov, Z.Y. Almstead, K.J. Gu, R.
`Mabon, M. Gardyan, B.D. Hamman, J. Allen, S. Gopinathan, B. McKnight, M.
`Crist, Y. Zhang, Y. Liu, J. Zhou, N. Paten, Q. Liu, A.G.E. Wilson, S.D. Kimball,
`D.S. Rice, D.B. Rawlins. A Novel Class of LIM-kinase 2 Inhibitors for the
`Treatment of Ocular Hypertension and Associated Glaucoma. J. Med. Chem
`2009 (52) 6515-6518.
`
`15. Z.-C. Shi, A. Devasagayaraj, K. Gu, H Jin, B. Marinelli, L. Samala, S. Scott, T.
`Stouch, A. Tunoori, Y. Wang, Y. Zang, C. Zhang, S.D. Kimball, A.J. Main, W.
`Sun, Q. Yang, A. Nouraldeen, X.-Q. Yu, E. Buxton, S. Patel, N. Nguyen, J.
`Swaffield, D.R. Powell, A. Wilson, Q. Liu. Modulation of Peripheral Serotonin
`
`CONFIDENTIAL
`
`4 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment
`of Functional Gastrointestinal Disorders. J. Med. Chem. 2008 (51) 3684-3687.
`
`16. B.E. Fink, A.V. Gavai, J.S. Tokarski, B. Goyal, R. Misra, H-Y. Xiao, S.D.
`Kimball, W-C. Han, D. Norris, T.E. Spires, D. You, M.M. Gottardis, M.V.
`Lorenzi, G.D. Vite. Identification of a Novel Series of Tetrahydrodibenzazocines
`as Inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg. Med. Chem.
`Lett. 2006 (16) 1532-1536.
`
`17. R.N. Misra, H.Y. Xiao, K.S. Kim, S. Lu, W.C. Han, S.A. Barbosa, J.T. Hunt,
`D.B. Rawlins, W. Shan, S.Z. Ahmed, L. Qian, B.C. Chen, R. Zhao, M.S. Bednarz,
`K.A. Kellar, J.G. Mulheron, R. Batorsky, U. Roongta, A. Kamath, P. Marathe, S.
`A. Ranadive, J. S. Sack, J.S. Tokarski, N.P. Pavletich, F.Y.F. Lee, K.R. Webster,
`S.D. Kimball. N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-
`Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-
`thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and
`Selective Antitumor Agent. J. Med. Chem. 2004 (47) 1719-1728.
`
`18. R. N. Misra, H. Y. Xiao, D. K. Williams, K. S. Kim, S. Lu, K. A. Kellar, J. G.
`Mulheron, R. Batorsky, S. D. Kimball, F. Y. Lee, K. R. Webster. Synthesis and
`Biological Activity of N-Aryl-2-Aminothiazoles. Pan Inhibitors of Cyclin-
`Dependent Kinases. Bioorg. Med. Chem. Lett. 2004 (14) 2973-77.
`
`19. R. N. Misra, H. Y. Xiao, D. B. Rawlins, W. Shan, K. A. Kellar, J. G. Mulheron, J.
`S. Sack, J. S. Tokarski, S. D. Kimball, K. R. Webster. 1H-Pyrazolo[3,4-
`b]pyridine Inhibitors of Cyclin-dependent Kinases. Highly Potent 2,6-
`Difluorophenacyl Analogues. Bioorg. Med. Chem. Lett. 2003 (13) 2405-2408.
`
`20. R. N. Misra, D. B. Rawlins, H. Y. Xiao, W. Shan, I. Bursuker, K. A. Kellar, J. G.
`Mulheron, J. S. Sack, J. S. Tokarski, S. D. Kimball, K. R. Webster. 1H-
`Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med.
`Chem. Lett. 2003 (13) 1133-1136.
`
`21. W.G. Humphreys, M.T. Obermeier, S. Chong, S.D. Kimball, J. Das, P. Chen, R.
`Moquin, W.-C. Han, R. Gedamke, R.E. White, R.A. Morrison. Oxidative
`Activation of Acylguanidine Prodrugs: Intestinal Presystemic Activation in Rats
`Limits Absorption and can be Inhibited by Co-administration of Ketoconazole.
`Xenobiotica, 2003 (33) 93-106.
`
`22. K.S. Kim, S.D. Kimball, R.N. Misra, D.B. Rawlins, J.T. Hunt, H.Y. Xiao, S. Lu,
`L. Qian, W.C. Han, W. Shan, T. Mitt, Z.W. Cai, M.A. Poss, H. Zhu, J.S. Sack,
`J.S. Tokarski, C.Y. Chang, N. Pavletich, A. Kamath, W.G. Humphreys, P.
`Marathe, I. Bursuker, K.A. Kellar, U. Roongta, R. Batorsky, J.G. Mulheron, D.
`Bol, C.R. Fairchild, F.Y. Lee, K.R. Webster. Discovery of Aminothiazole
`Inhibitors of Cyclin Dependent Kinase 2: Synthesis, X-ray Crystallographic
`Analysis and Biological Activities. J Med Chem. 2002 (45) 3905-3927.
`
`CONFIDENTIAL
`
`5 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`23. J. Das, S.D. Kimball, J.A. Reid, W.F. Lau, D. Roberts, S.M. Seiler, W.A.
`Schumacher, M.L. Ogletree. Thrombin Active Site Inhibitors: Chemical
`Synthesis, In vitro and In vivo Pharmacological Profile of a Novel and Selective
`Agent BMS-189090 and Analogs. Bioorg. & Med. Chem. Lett., 2002 (12) 45-49.
`
`24. J. Das, S.D. Kimball, S. E. Hall, W-C. Han, E. Iwanowicz, J. Lin, R.V. Moquin,
`J.A. Reid, J.S. Sack, M.F. Malley, C.Y. Chang, S. Chong, D.V. Wang-Iverson,
`D.G.M. Roberts, S.M. Seiler, W.A. Schumacher, M.L. Ogletree. Molecular
`Design and Structure Activity Relationships Leading to the Potent, Selective and
`Orally Active thrombin Active Site Inhibitor BMS-189664. Bioorg. & Med.
`Chem. Lett., 2002 (12) 45-49.
`
`25. S.D. Kimball and K.R. Webster. Cell Cycle Kinases and Checkpoints. Annual
`Reports in Medicinal Chemistry 2001 (36) 139-148.
`
`26. P. Eller, S. Berjukov, S. Wanner, I. Huber, S. Hering, H-G. Knaus, G. Toth, S.D.
`Kimball, J. Striessnig. High Affinity Interaction of Mibefradil with Voltage-
`Gated Calcium and Sodium Channels. British Journal of Pharmacology 2000
`(130) 669-677.
`
`27. K.S. Kim, J.S. Sack J.S. Tokarski, L. Qian, S.T. Chao, L Leith, Y.F. Kelly, R.N.
`Misra, J.T. Hunt, S.D. Kimball, W.G. Humphreys, B.S. Wautlet, J.G. Mulheron,
`K.R. Webster. Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective
`Inhibitors: Synthesis and biological Effects. J Med Chem. 2000 (43) 4126-4134.
`
`28. K.R. Webster and S.D. Kimball. “Novel Drugs Targeting the Cell Cycle”.
`Emerging Drugs 2000 (5) 45-59.
`
`29. T. Brauns, H. Prinz, S.D. Kimball, R.P. Haugland, J. Striessnig, H. Glossmann.
`L-type calcium channels: Binding Domains for Dihydropyridines and
`Benzothiazepines are Located in Close Proximity to Each Other. Biochemistry
`1997 (36) 3625-3631.
`
`30. R. Kraus, B. Reichl, S.D. Kimball, M. Grabner, W.A. Catterall, J. Striessnig.
`Identification of Benz(othi)azepine Binding Regions within L-type Calcium
`Channel Alpha1 Subunits. Journal of Biological Chemistry, 1996 (271) 20113-
`20118.
`
`31. S.D. Kimball. Thrombin Active Site Inhibitors. Current Pharmaceutical Design
`1995 (1) 441-468.
`
`32. S.D. Kimball. Challenges in the Development of Orally Bioavailable Thrombin
`Active Site Inhibitors. Blood Coagulation and Fibrinolysis, 1995 (6) 511-519.
`
`33. J. Das, S.D. Kimball. Thrombin Active Site Inhibitors. Bioorg. Med. Chem. 1995
`(3) 999-1007.
`
`34. T. Brauns, Z.W. Cai, ; S.D. Kimball, H.C. Kang, R.P. Haugland, W. Berger, S.
`Berjukov, S. Hering, H. Glossmann, J. Striessnig. The Benzothiazepinone
`
`CONFIDENTIAL
`
`6 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Binding Domain of Purified L-type Calcium Channels: Direct Labeling Using a
`Novel Fluorescent Diltiazem Analogue. Biochemistry 1995 (34) 3461-3469.
`
`35. G.C. Rovnyak, S.D. Kimball, B. Beyer, G. Cucinotta, J.D. DiMarco, J.Z.
`Gougoutas, A. Hedberg, M. Malley, J.P. McCarthy, R. Zhang, S. Moreland.
`Calcium Entry Blockers and Activators: Conformational and Structural
`Determinants of Dihydropyrimidine Calcium Channel Modulators. J. Med.
`Chem. 1995 (38) 119-129.
`
`36. S.D. Kimball, J.C. Barrish, J.T. Hunt, D.M. Floyd, J.Z. Gougoutas, and W.F. Lau.
`"The Design of New Calcium Antagonists" in Ion Channels in the
`Cardiovascular System: Function and Dysfunction. P.M. Spooner and A.M.
`Brown (eds). Futura Press, 1994, Armonk, N.Y.
`
`37. S.D. Kimball, J.T. Hunt, J.C. Barrish, J. Das, D.M. Floyd, M.W. Lago, V.G. Lee,
`S.H. Spergel, S. Moreland, S.A. Hedberg, J.Z. Gougoutas, M.F. Malley, W.F.
`Lau. 1-Benzazepin-2-one Calcium Channel Blockers. VI. Receptor-Binding
`Model and Possible Relationship to Desmethoxyverapamil. Bioorg. & Med.
`Chemistry 1993 (1), 285-307.
`
`38. A.A. Tymiak, J.G. Tuttle, S.D. Kimball, T. Wang and V.G. Lee. A Simple and
`Rapid Screen for Inhibitors of Factor XIIIa. J. Antibiotics 1993 (46) 505-507.
`
`39. S.D. Kimball, D.M. Floyd, J. Das, J.T. Hunt, J. Krapcho, G. Rovnyak, K.J. Duff,
`V.G. Lee, R.V. Moquin, C.F. Turk, S.A. Hedberg, S. Moreland, R.J. Brittain,
`D.M. McMullen, D.E. Normandin, G. Cucinotta. Benzazepinone Calcium
`Channel Blockers. 4. Structure-Activity Overview and Intracellular Binding Site.
`J. Med. Chem. 1992 (35) 780-793.
`
`40. D.M. Floyd, S.D. Kimball, J. Krapcho, J. Das, C.F. Turk, R.V. Moquin, M.W.
`Lago, K.J. Duff, V.G. Lee, R.E. White, R.E. Ridgewell, S. Moreland, R.J.
`Brittain, D.E. Normandin, S. A. Hedberg, G. Cucinotta. Benzazepinone Calcium
`Channel Blockers. 2. Structure-Activity and Drug Metabolism Studies Leading to
`Potent Antihypertensive Agents. Comparison with Benzothiazepinones. J. Med.
`Chem. 1992 (35) 756-772.
`
`41. K. Atwal, G. Rovnyak, S.D. Kimball, D.M. Floyd, S. Moreland, B. Swanson, J.
`Gougoutas, J. Schwartz, K. Smillie, M. Malley. Dihydropyrimidine Calcium
`Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-
`pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines. J. Med.
`Chem. 1990 (33) 2629-2635.
`
`42. S. Moreland, M. Ushay, S.D. Kimball, J.R. Powell, and R.S. Moreland. Pressor
`Reponses Induced by Bay k 8644 Involve both Release of Adrenal
`Catecholamines and Calcium Channel Activation. Brit. J. Pharm. 1988 (93) 994-
`1004
`
`CONFIDENTIAL
`
`7 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`43. S.D. Kimball, D.R. Walt, F. Johnson. Anthracyclines and Related Substances. 3.
`Regiospecific Total Synthesis of 11-Deoxydaunomycinone. J. Am. Chem. Soc.
`1981 (103) 1561-63.
`
`44. C. Becker-Carus, S.D. Kimball, U. Gillich and N. Matussek. Wirkung von
`Alphamethyltyrosin auf das Lernverhalten und die Hippocampusaktivitaet.
`Psychopharmacologia 1972 (27) 53-66.
`
`45. S.J. Suomi, H.F. Harlow and S.D. Kimball. Behavioral Effects of Prolonged
`Partial Social Isolation in the Rhesus Monkey. Psych Reports 1971 (29) 1171-77.
`
`
`
` SELECT PATENTS
`
`Substituted Xanthines and Methods of Use Thereof. B.L. Chenard, R.J. Gallaschun, S.D.
`Kimball. US2014/0275528A1. September 18, 2014.
`
`Inhibiting Transient Receptor Potential Ion Channel TRPA1. C.A. Metcalf III, Y.G. Gu,
`S. D. Kimball, Q. Li, B.S. Lippa, D. Ryan, X. Wu, D. Zou. US2013/0274273.
`October 17, 2013.
`
`Compounds useful for treating disorders related to TRPA1. X. Wu, S.D. Kimball, P.
`Chen, D. Zhou, S. Peng. US 8,530,487. September 10, 2013.
`
`Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 Inhibitors. B.A. Harrison, S.D.
`Kimball, R. Mabon, D.B. Rawlins, D.S. Rice, M.V. Voronkov, Y. Zhang. US
`8,507,672. August 13, 2013.
`
`Modulators of G Protein-coupled Receptor 88. Y. Bi, C.D. Dzierba, J.J. Bronson, K.
`Carson, G. Cianchetta, L. Dong, C. Fink, M. Green, D. Kimball, J.E. Macor, S.
`Kwon. US 8,297,271. July 30, 2013.
`
`Sulfanyl-tetrahydropyran-based Compounds and Methods of Their Use. B.A. Harrison,
`S.D. Kimball, R. Mabon, D.B. Rawlins. US 8,476,413. July 2, 2013.
`
`(7H-pyrrolo[2,3-D]pyrimidin-4-yl) piperazines as Kinase Inhibitors for the Treatment of
`Cancer and Inflammation. B.A. Harrison, S.D. Kimball, R. Mabon, D.B. Rawlins,
`D. Rice, M.V. Voronkov, Y. Zhang. EP 13155538.5-1451 published April 10, 2013.
`
`Methods of Treating Ulcerative Colitis. D.J. Augeri, J. Bagdanoff, L.W. Boteju, K.G.
`Carson, T.C. Jessop, S.D. Kimball. US 8,404,732. March 26, 2013.
`
`Modulators of G Protein-Coupled Receptor 88. C.D. Dzierba, R.A. Hartz, Y. Bi, V.T.
`Ahuja, J.J. Bronson, K. Carson, G. Cianchetta, M. Green, D. Kimball, S.R. Kimura,
`S. Kwon, J.E. Macor, Y. Zhang, G. Zipp. US 8,304,577. November 6, 2012.
`
`CONFIDENTIAL
`
`8 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Imidazole based compounds, compositions comprising them and methods of their use.
`D.J Augeri, J. Bagdanoff, L. Boteju, K. Carson, T. Jessop, S.D. Kimball. US
`7,649,098. January 19, 2010.
`
`Preparation of piperazinylpyrrolopyrimidines as LIM kinase 2 inhibitors. B.A.
`Harrison, S.D. Kimball, R. Mabon, D.B. Rawlins, D.S. Rice, M.V. Voronkov, Y.
`Zhang. PCT Int. Appl. (2009),WO2009021169 A220090212.
`
`Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of their Use. B.A. Harrison,
`S.D. Kimball, R. Mabon, D.B. Rawlins, US 7,781,577 B2. August 24, 2010.
`
`Process for preparing Azacycloalkanoylaminothiazoles, B.C. Chen, K.S. Kim, S.D.
`Kimball, R.N., Misra, M.E. Salvati, J.E. Sundeen, H.Y. Xiao, R. Zhao. US 6,897,321
`B2, May 24, 2005.
`
`Cyano-substituted Dihydropyrimidine Compounds and their Use to Treat Diseases, S.D.
`Kimball, L.J. Lombardo, D.B. Rawlins, H.Y. Xiao, R.J. Schmidt, D.K. Williams.
`US 6,809,102 B2, October 26, 2004.
`
`Carbon Substituted Aminothiazole Inhibitors of Cyclin Dependent Kinases. D.B.
`Rawlins, S.D. Kimball, R.N. Misra, K.S. Kim, K.R. Webster. US 6,720, 347 B2,
`April 13, 2004.
`
`Process for preparing Arylacetylaminothiazoles, B.C. Chen, K.S. Kim, S.D. Kimball,
`R.N. Misra, J.E. Sundeen, R. Zhao. US 6,613,911 B2, September 2, 2003.
`
`Aminopyrazole Inhibitors of Cyclin Dependent Kinases. M.E. Salvati, S.D. Kimball.
`US 6,610,724 B2, August 26, 2003.
`
`Methods for Preventing and Treating Alopecia induced by Chemotherapy or
`Radiotherapy. S.D. Kimball, K.R. Webster, D.K. Bol. US 6,534,531 B2, March 18,
`2003.
`
`Alkylsulfonamido Heterocyclic Thrombin Inhibitors. S.D. Kimball, J. Das, W.F. Lau,
`US 6,534,536 B1, March 18, 2003.
`
`Aminothiazole Inhibitors of Cyclin Dependent Kinases. K.S. Kim, S.D. Kimball, Z.W.
`Cai, D.B. Rawlins, R.N. Misra, M.R. Poss, K.A. Webster, J.T. Hunt, W.C. Han. US
`6,521,759 B2, February 18, 2003.
`
`Disubstituted Heterocyclic Thrombin Inhibitors. J. Das, S.D. Kimball, W.F. Lau. US
`5,691,356. November 25, 1997.
`
`
`
`CONFIDENTIAL
`
`9 of 9
`
`PENN EX. 2029
`CFAD V. UPENN
`IPR2015-01836